News

Barclays Predicts Gradual Recovery in European Earnings Ahead

Barclays Predicts Gradual Recovery in European Earnings Ahead

Barclays Predicts Gradual Recovery in European Earnings Ahead

Barclays, a well-known financial institution, has recently revised its earnings per share (EPS) growth estimates for Europe, projecting a modest 2% for the fourth quarter of 2024. This reduction comes in contrast to a slightly more optimistic 8% cut in the United States. The adjustments signal the challenges faced by the European market, stemming from widespread guidance cuts and a lackluster economic landscape.

Understanding the Current Earnings Landscape

Interestingly, despite these hurdles, there are emerging signs of potential recovery. Investors are keenly anticipating insights into the 2025 outlook, especially given that earnings growth has been stagnant in the previous year. This stagnation has significantly impacted the performance of European equities since the second half of the year.

Strategists led by Emmanuel Cau from Barclays suggest that, although difficult situations persist, there are expansionary global Purchasing Managers' Indexes (PMIs) and positive year-over-year base effects. Such factors may enable mild EPS growth for Europe, pointing toward a path of gradual improvement.

Potential Tailwinds for European Earnings

Recent fourth-quarter economic data has outperformed expectations, and a weaker euro and pound against the US dollar could serve as tailwinds for European earnings, particularly benefitting exporters. Barclays notes that the noticeable weakness in these currencies is not fully incorporated into current earnings estimates, indicating optimism for future adjustments.

Looking further into 2025, Barclays projects a 4% growth in European earnings, slightly lower than the 7% IBES consensus. This outlook is bolstered by expectations of global nominal GDP growth remaining near the 5% trend, which the firm anticipates will help stabilize margins and support mid-single-digit earnings growth levels.

Navigating Challenges Ahead

However, there are cautions ahead. Weak domestic demand, ongoing uncertainties surrounding trade, and fluctuations in Chinese market activity may continue to put pressure on performance. Additionally, the current high-interest rate environment could add to the difficulties faced by earnings as they strive to drive positive market movements.

Despite these challenges, Barclays believes that much of the adverse factors have already been priced into European equities. As a result, should conditions improve, there remains significant potential for modest re-rating of these assets.

Sector-Specific Insights and Recommendations

Barclays strategists have noted that while European valuations may not seem overly aggressive, the ongoing narrative of persistently high rates emphasizes the necessity for earnings growth to propel market upsides this year. In 2025, cyclicals are expected to outperform defensives in the earnings growth arena, although the recent uptick in valuations for cyclicals has created a tighter margin for error.

In terms of investment recommendations, Barclays is taking a selective approach, favoring sectors such as dollar earners, luxury goods, technology, and short-cycle segments like chemicals and capital goods. Furthermore, the gradual rollout of trade tariffs and potential economic stimuli from China could provide additional support for these sectors.

Highlighting Growth Sectors

Opportunities remain in utilities, energy services, financials, and real estate, where robust earnings growth is expected. Conversely, outlooks for areas like technology hardware and automotive sectors are more cautious, reflecting specific challenges that these industries face.

Frequently Asked Questions

What are Barclays' EPS growth projections for Europe?

Barclays currently forecasts a 2% EPS growth for Europe for Q4 2024.

Why does Barclays expect a recovery in European earnings?

Barclays sees potential recovery due to expansionary global PMIs and the influence of currency weakness against the US dollar.

What factors might affect European earnings in 2025?

Weak domestic demand, trade uncertainties, and high-interest rates are significant factors that could impact European earnings.

Which sectors does Barclays recommend investing in?

Barclays recommends focusing on dollar earners, luxury, technology, and short-cycle plays, among others.

What is the expected earnings growth for the 2025 outlook?

Barclays expects a 4% increase in European earnings for 2025, lower than the IBES consensus of 7%.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Nonprofit and Partners Gift Homes to Veterans

Updated Category News Views 100

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

Continue Reading
Surprising Week on Wall Street: Chips Drive Gains

Updated Category News Views 141

A Wild Week in Wall Street Well, folks, what a week it’s been on Wall Street. The indexes danced the cha-cha, making gains despite closing Friday on a lower note. Despite the retreat, we've got ourselves a week where the major indexes closed higher than the previous Friday. It's not the usual story, but who ever thought stocks played by the rules? The Nasdaq Composite...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 141

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 83

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Updated Category News Views 66

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 99

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 155

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Gemmy's Holiday Lights: Bright Ideas for 2026

Updated Category News Views 149

Deep in the heart of Dallas, Gemmy Industries is out to sprinkle a bit of magic over the holiday season for 2026. This ain't your grandma's string lights we're talkin' about here. We're diving headfirst into a new world of seasonal decor with tech-driven lights that look like they came straight outta a winter wonderland. And hey, if Walmart's set to host this lineup, you...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 177

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading

Top 5 Most Recently Viewed Articles

NexPoint Capital Launches Tender Offer for Shareholders

Updated Category News Views 217

NexPoint Capital Begins Tender Offer for Its Common Stock NexPoint Capital, Inc. (the "Company"), a publicly registered business development company expertly managed by NexPoint Advisors, L.P., is set to kick off a voluntary tender offer aimed at going after up to 2.5% of its outstanding common shares. This offer is designed to provide shareholders an opportunity to sell...

Continue Reading
Experience the Winter Wheat Wonderland Pop-Up by Maker's Mark

Updated Category News Views 223

Immerse Yourself in Maker's Mark's Winter Wheat Wonderland Get ready to experience something truly unique this holiday season as Maker's Mark unveils its enchanting pop-up event, the Winter Wheat Wonderland. This special event will take the vibrant spirit of Kentucky bourbon to the heart of New York City, creating a magical atmosphere for all attendees. Details of the...

Continue Reading
Innovative Muscle Composition Study Enhances Liver Transplant Care

Updated Category News Views 202

Assessment of Muscle Composition in Liver Transplant Candidates In a groundbreaking study, the utilization of AMRA Profiler 4, an advanced body-composition analysis device, was analyzed for its effectiveness in evaluating muscle composition among liver transplant candidates suffering from end-stage liver disease (ESLD). This study aims to shed light on critical health...

Continue Reading
Hansa Biopharma's Major Milestones Anticipated in 2025

Updated Category News Views 688

Hansa Biopharma's Participation in Healthcare Conferences Hansa Biopharma AB, a pioneering biopharmaceutical company, is set to make a significant presence at the 2025 J.P. Morgan Healthcare Conference. The company is renowned for its innovative approaches in addressing rare immunological disorders and has been actively engaged in developing novel therapies. This...

Continue Reading
AI for Customer Service: The Next Big Market Leap Ahead

Updated Category News Views 137

AI for Customer Service Market Growth Overview The AI for customer service market is on a remarkable trajectory, set to expand significantly over the next few years. Current projections indicate that the market size will grow from USD 12.06 billion in the near term to an impressive USD 47.82 billion by the end of the decade, achieving a compound annual growth rate (CAGR)...

Continue Reading